A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Saved in:
| Title: | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. |
|---|---|
| Authors: | Chan, Stephen L.1 (AUTHOR) chanlam_stephen@cuhk.edu.hk, Schuler, Martin2 (AUTHOR), Kang, Yoon-Koo3 (AUTHOR), Yen, Chia-Jui4 (AUTHOR), Edeline, Julien5 (AUTHOR), Choo, Su Pin6 (AUTHOR), Lin, Chia-Chi7 (AUTHOR), Okusaka, Takuji8 (AUTHOR), Weiss, Karl-Heinz9 (AUTHOR), Macarulla, Teresa10 (AUTHOR), Cattan, Stéphane11 (AUTHOR), Blanc, Jean-Frederic12 (AUTHOR), Lee, Kyung-Hun13 (AUTHOR), Maur, Michela14 (AUTHOR), Pant, Shubham15 (AUTHOR), Kudo, Masatoshi16 (AUTHOR), Assenat, Eric17 (AUTHOR), Zhu, Andrew X.18,19 (AUTHOR), Yau, Thomas20 (AUTHOR), Lim, Ho Yeong21 (AUTHOR) |
| Source: | Journal of Experimental & Clinical Cancer Research (17569966). 6/2/2022, Vol. 41 Issue 1, p1-19. 19p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17569966 |
|---|---|
| DOI: | 10.1186/s13046-022-02383-5 |
